Clinical Trial Update: Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and tolerability of intraprostatic PRX302 in men with low to intermediate risk prostate cancer has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• PRX302

Snippet

Sponsor: Sophiris Bio Corp | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED